Clinical Nurse Specialist in Castle Pines, CO Accepting Medicare

1 Clinical Nurse Specialist nurses found. Showing 1 - 1

Mrs. Elisabeth Susanne Littleton, AGCNS-BC, APRXN Clinical Nurse Specialist - Gerontology Medicare: Not Enrolled in Medicare Practice Location: 6415 Montano Pl, Castle Pines, CO 80108 Phone: 720-635-2968    Fax: 720-200-4906

News Archive

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014.

Intelligent t-shirt patient biomonitoring platform

Using this garment-based patient biomonitoring platform allows us to register a number of the patient's physiological parameters in a non-intrusive manner. "The information gathered by an intelligent t-shirt using e-textile technology is sent, without using wires, to an information management system, which then shows the patient's location and vital signs in real time", explain the UC3M researchers.

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris Inc. today announced a strategic co-promotion services agreement with ASCEND Therapeutics US, LLC.

Tolera Therapeutics granted orphan drug status for organ transplant rejection lead candidate drug

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation.

Read more Medical News

› Verified 4 days ago